Does bedside testing for H-FABP improve risk stratification for adverse outcomes in non-high-risk patients with acute PE?
Bedside H-FABP testing, especially when integrated into a novel score, is useful for rapid risk stratification of non-high-risk acute pulmonary embolism without needing echocardiography.
Bedside testing for H-FABP appears a useful tool for immediate risk stratification of non-high-risk patients with acute PE, who may be at increased risk of an adverse outcome, in particular if integrated in a novel score without the need of echocardiographic examination.
Lankeit et al. (2012) studied this question.